ELUVIA™
Drug-Eluting Vascular Stent System
Sustained drug release to reduce restenosis
Restenosis following nitinol stenting in the SFA peaks at ~12 months1
![Clinical History of Restenosis](https://www.bostonscientific.com/en-EU/products/stents-vascular/eluvia-drug-eluting-stent-system/sustained-drug-release/_jcr_content/maincontent-par/image_copy.img.Clinical%20history%20of%20restenosis.png)
The Eluvia™ stent system was designed to sustain drug release when restenosis is most likely to occur.1
![DRUG TISSUE CONCENTRATIONS OVER TIME](https://www.bostonscientific.com/en-EU/products/stents-vascular/eluvia-drug-eluting-stent-system/sustained-drug-release/_jcr_content/maincontent-par/image_0.img.Eluvia%27s%20elution%20period.png)
Eluvia has the lowest drug dose density of any PTX therapy2
![Eluvia DES](https://www.bostonscientific.com/en-EU/products/stents-vascular/eluvia-drug-eluting-stent-system/sustained-drug-release/_jcr_content/maincontent-par/image_1061157613_cop.img.Eluvia_lowest_drugs.png)